CK19 CYFRA21-1 IVD Rapid Test Kit IFA Colloidal Gold POCT
Diagnostic Reagent Cassette
Soluble forms of keratins in human sera seem to be useful analytes
for the monitoring of cancer patients. CYFRA 21-1 is a new test
measuring keratin 19 in human blood. The test was developed as
sandwich ELISA based on two monoclonal antibodies, both reacting
with keratin 19. The epitopes recognised
Why Choose WWHS
Our company's main business is INFRARED fluorescent POCT. The main
application scenarios of POCT include emergency department, ICU,
chest pain center and stroke center, operating room, and various
departments of grade hospitals. Community health, outpatient and
other primary medical institutions at all levels; Pharmacies, home
use and other organizations and individuals targeted at end
customers. POCT is characterized by its simplicity and speed,
freedom from application scenarios, and high cost performance.
However, the current pain point of POCT industry lies in how to
solve the problems of low sensitivity and poor precision faced by
POCT products.
About NIR-1000 Dry Fluoroimmunoassay Analyser
It is a fluorescence immunochromatographic analysing system with
internal temperature control,
which can help diagnose conditions such as infection, diabetes,
cardiovascular diseases, renal injury and cancers, etc.
Immunofluorescence technology
Testing time less than 15 minutes
Easy-to-use touch-screen platform,multi-language system
Reagents stored at room temperature for 12 months
| Assay list | | | | | |
| Tumor Marker | | | | | |
| cat#. | Product Item | Specimen | Reaction Time | Measure Range | Clinical Range | Itended Use |
| 20 | AFP | Serum/Plasma | 15min. | 2.5-200ng/ml | <20ng/ml | pregnancy cancer |
| 21 | CEA | Serum/Plasma | 15min. | 1-200ng/ml | <5ng/ml | colon cancer, colorectal cancer,etc. |
| 22 | NSE | Serum/Plasma | 15min. | 1-400ng/ml | <16ng/ml | non-small cell lung cancer |
| 23 | FOB | fecal specimens | 10min. | 50-1000ng/ml | <100ng/ml | Abnormal recessive gastrointestinal bleeding |
| 24 | PG II | Serum/Plasma | 15min. | 1-100ug/L | PGI/PGII>3.0 | gastric abnormalities |
| 25 | PG I | Serum/Plasma | 15min. | 2.5-200ug/L | >70ng/ml | gastric abnormalities |
| 26 | TPSA | Serum/Plasma | 15min. | 0.5-40ng/ml | <4ng/ml | prostate cancer |
| 27 | FPSA | Serum/Plasma | 15min. | 0.1-10ng/ml | <1ng/ml | prostate cancer |
| 28 | CA12-5 | Serum/Plasma | 15min. | 20-500U/ml | <35U/ml | ovarian cancer |
| 29 | CA15-3 | Serum/Plasma | 15min. | 10-400U/ml | < 25 U/mL | breast cancer |
| 30 | HE4 | Serum/Plasma | 15min. | 50-2000pmol/L | <140 pmol/L | ovarian cancer |
| 31 | CA19-9 | Serum/Plasma | 15min. | 10-400U/ml | < 27 U/mL | pancreatic cancer |
| 32 | β-HCG | Serum/Plasma | 15min. | 5-400mIU/ml | <10 mIU/mL | Early pregrancy, ectopic HCG cancer,incomplete abortion |
| 33 | CK19(Cyfra21-1) | Serum/Plasma | 15min. | 0.5-50ng/ml | <2.5ng/ml | non-small cell lung cancer |
